0001558370-23-020006.txt : 20231226 0001558370-23-020006.hdr.sgml : 20231226 20231226065621 ACCESSION NUMBER: 0001558370-23-020006 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231226 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231226 DATE AS OF CHANGE: 20231226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001006281 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 650643773 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33357 FILM NUMBER: 231511306 BUSINESS ADDRESS: STREET 1: 2 UNIVERSITY PLAZA STREET 2: SUITE 100 CITY: HACKENSACK STATE: NJ ZIP: 07601 BUSINESS PHONE: 201-696-9345 MAIL ADDRESS: STREET 1: 2 UNIVERSITY PLAZA STREET 2: SUITE 100 CITY: HACKENSACK STATE: NJ ZIP: 07601 FORMER COMPANY: FORMER CONFORMED NAME: ORTHODONTIX INC DATE OF NAME CHANGE: 19980422 FORMER COMPANY: FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP DATE OF NAME CHANGE: 19960124 8-K 1 plx-20231226x8k.htm 8-K
0001006281false00010062812023-12-262023-12-26

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 26, 2023

Protalix BioTherapeutics, Inc.

(Exact name of registrant as specified in its charter)

​

​

​

​

​

​

Delaware

    

001-33357

    

65-0643773

(State or other jurisdiction
of incorporation)

​

(Commission File Number)

​

(IRS Employer
Identification No.)

​

​

​

​

​

2 University Plaza

​

​

​

​

Suite 100

​

​

​

​

Hackensack, NJ

​

​

​

07601

(Address of principal executive offices)

​

​

​

(Zip Code)

​

 Registrant’s telephone number, including area code 201-696-9345

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, $0.001 par value

PLX

NYSE American

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

​

​

Item 7.01

Regulation FD Disclosure

On December 26, 2023, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release containing a copy of a letter that the Company released to its stockholders. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (“Current Report”).

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits

​

Exhibit No.

 

Description

​

99.1

​

Press Release dated December 26, 2023

104

​

Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 26, 2023

PROTALIX BIOTHERAPEUTICS, INC.

​

​

 

 

 

 

 

By:

/s/ Dror Bashan

 

 

Name:

Dror Bashan

 

 

Title:

President and
Chief Executive Officer

​

​

 EX-99.1 2 plx-20231226xex99d1.htm EX-99.1

​

​

Graphic

Exhibit 99.1

​

Protalix BioTherapeutics Issues 2024 Letter to Stockholders

CARMIEL, Israel, December 26, 2023 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders.

December 26, 2023

Dear Protalix Stockholders,

As we approach the close of a transitional year for our company, I want to take a moment to reflect on our recent accomplishments…accomplishments that are shaping our path going forward. Elfabrio®, our second development candidate produced through our proprietary ProCellEx® plant cell-based protein expression system, was approved for the treatment of adult patients with Fabry disease by both the U.S. Food and Drug Administration and the European Medicines Agency. Approval of Elfabrio marks a significant milestone for our company and, more importantly, brings a new therapeutic option to patients with unmet needs. This achievement is a testament to the tireless efforts of our talented and professional team, and we take great pride in sharing this success with you, our dedicated stockholders.

As Elfabrio has moved from the development stage to being a commercial product, we are taking steps we believe will strengthen our internal operations and improve our production capabilities for two commercial products. We are confident that as the commercialization of Elfabrio continues to develop, it will enable us to improve our capital structure.

Our commercial partner, Chiesi Global Rare Diseases, played a pivotal role in our journey, and I extend my gratitude to Giacomo Chiesi and the entire Chiesi team. Their support has been instrumental in our combined success, and we look forward to further strengthening our relationship in the years to come. Since the approval, Chiesi has launched Elfabrio in the United States, the European Union and the United Kingdom, strategically positioning Elfabrio for success in those markets. Protalix is dedicated to being a valuable resource to Chiesi and facilitating Chiesi’s commercial efforts.

We are continuing to make progress on our pipeline programs. We have finished the seventh cohort in the phase I clinical trial of PRX-115, our recombinant PEGylated uricase (urate oxidase) under development for the potential treatment of severe gout. At this time, 56 patients have been dosed in this trial and we anticipate completing the trial in the second quarter of 2024. Progress is also being made in the preclinical development of PRX-119, our plant cell-expressed PEGylated recombinant human DNase I product candidate which we are designing to elongate half-life in the circulation for NETs-related diseases. We look forward to updating you as we advance in the development of these and other product candidates, and as we begin to turn our focus to building a sustainable portfolio of treatments for rare diseases.

I also want to take a moment to acknowledge the challenges our community continues to face given the current situation in Israel. Our hearts are with all those who have been affected so profoundly, including our colleagues, partners and the broader community. We deeply appreciate the impact of these events on both a personal and professional level, and we continue to extend our support to everyone navigating these difficult times.

Looking ahead, the future of Protalix is filled with promise and potential. As we continue to innovate and strengthen our operations, I am confident that our company can deliver impactful solutions for the benefit of patients in need. Our commitment to excellence, coupled with the passion of our team, positions us well for continued growth and success.

In closing, I want to express my sincere appreciation for our employees and our Board of Directors for their ongoing dedication to our mission. I also want to thank you, our stockholders, for your continued confidence and trust in our vision. As we navigate the exciting journey ahead, I am optimistic about Protalix’s future and the positive impact we can collectively make in the lives of patients and the broader healthcare community.

Thank you for your continued support. I hope you enjoy the holidays and have a happy new year.

Sincerely,

Dror Bashan, President & Chief Executive Officer

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix’s first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix’s second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023.

Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others.

Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms “expect,” “anticipate,” “believe,” “estimate,” “project,” “may,” “plan,” “will,” “would,” “should” and “intend,” and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings for the clinical trial. Factors that might cause material differences include, among others: risks related to the commercialization of Elfabrio, our approved product for the treatment of adult patients with Fabry disease; risks relating to Elfabrio’s market acceptance, competition, reimbursement and regulatory actions, including as a result of the boxed warning contained in the FDA approval received for the product; risks related to our commercialization partner’s ability to obtain and maintain reimbursement for Elfabrio, and the extent to which patient assistance programs and co-pay programs are utilized; the possible disruption of our operations due to the war declared by Israel’s security cabinet against the Hamas terrorist organization located in the Gaza Strip, the military campaign against the Hezbollah and other terrorist activities and armed conflict, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors and customers; the likelihood that the FDA, EMA or other applicable health regulatory authorities will approve an alternative dosing regimen for Elfabrio; risks related to the regulatory approval and commercial success of our other product and product candidates, if approved; failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to

satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and/or lack of sufficient funding to finance our clinical trials; delays in the approval or potential rejection of any applications we file with the FDA, EMA or other health regulatory authorities for our other product candidates, and other risks relating to the review process; risks associated with the novel coronavirus disease, or COVID-19, outbreak and variants, which may adversely impact our business, preclinical studies and clinical trials; risks associated with global conditions and developments such as supply chain challenges, the inflationary environment and tight labor market, and instability in the banking industry, which may adversely impact our business, operations and ability to raise additional financing if and as required and on terms acceptable to us; risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital; risks relating to our evaluation and pursuit of strategic partnerships; the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics; risks relating to our ability to manage our relationship with our collaborators, distributors or partners, including, but not limited to, Pfizer and Chiesi; risks related to the amount and sufficiency of our cash and cash equivalents; risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness; risks relating to changes to interim, topline or preliminary data from clinical trials that we announce or publish; risks relating to the compliance by Fiocruz with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement; risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector; our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies and/or technologies by other companies; risks related to our supply of drug products to Pfizer; potential product liability risks, and risks of securing adequate levels of related insurance coverage; the possibility of infringing a third-party’s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties; risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere; and other factors described in our filings with the U.S. Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.

Investor Contact

Chuck Padala, Managing Director

LifeSci Advisors

646-627-8390

chuck@lifesciadvisors.com

Source: Protalix BioTherapeutics, Inc.

 GRAPHIC 3 plx-20231226xex99d1001.jpg GRAPHIC begin 644 plx-20231226xex99d1001.jpg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end EX-101.SCH 4 plx-20231226.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 plx-20231226_lab.xml EX-101.LAB EX-101.PRE 6 plx-20231226_pre.xml EX-101.PRE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Document and Entity Information
Dec. 26, 2023
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Dec. 26, 2023
Securities Act File Number 001-33357
Entity Registrant Name Protalix BioTherapeutics, Inc.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 65-0643773
Entity Address, Address Line One 2 University Plaza
Entity Address, Address Line Two Suite 100
Entity Address, State or Province NJ
Entity Address, City or Town Hackensack
Entity Address, Postal Zip Code 07601
City Area Code 201
Local Phone Number 696-9345
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.001 par value
Trading Symbol PLX
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
Entity Central Index Key 0001006281
Amendment Flag false
XML 8 R2.htm IDEA: XBRL DOCUMENT v3.23.4
N-2
Dec. 26, 2023
Cover [Abstract]  
Entity Central Index Key 0001006281
Amendment Flag false
Securities Act File Number 001-33357
Document Type 8-K
Entity Registrant Name Protalix BioTherapeutics, Inc.
Entity Address, Address Line One 2 University Plaza
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Hackensack
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07601
City Area Code 201
Local Phone Number 696-9345
Entity Emerging Growth Company false
XML 9 plx-20231226x8k_htm.xml IDEA: XBRL DOCUMENT 0001006281 2023-12-26 2023-12-26 0001006281 false 8-K 2023-12-26 Protalix BioTherapeutics, Inc. DE 001-33357 65-0643773 2 University Plaza Suite 100 Hackensack NJ 07601 201 696-9345 false false false false Common stock, $0.001 par value PLX NYSEAMER false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://protalix.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995470 - Disclosure - N-2 Sheet http://xbrl.sec.gov/cef/role/N2 N-2 Notes 2 false false All Reports Book All Reports plx-20231226.xsd plx-20231226_lab.xml plx-20231226_pre.xml plx-20231226x8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "plx-20231226x8k.htm": { "nsprefix": "plx", "nsuri": "http://protalix.com/20231226", "dts": { "schema": { "local": [ "plx-20231226.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/2006/xbrldi-2006.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/cef/2023/cef-2023.xsd", "https://xbrl.sec.gov/cef/2023/cef-2023_pre.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023_lab.xsd" ] }, "labelLink": { "local": [ "plx-20231226_lab.xml" ] }, "presentationLink": { "local": [ "plx-20231226_pre.xml" ] }, "inline": { "local": [ "plx-20231226x8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 208, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://protalix.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_12_26_2023_To_12_26_2023_pAL5-vpnDUaJhHAxg2HQTg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "plx-20231226x8k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_12_26_2023_To_12_26_2023_pAL5-vpnDUaJhHAxg2HQTg", "name": "dei:DocumentPeriodEndDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "plx-20231226x8k.htm", "unique": true } }, "R2": { "role": "http://xbrl.sec.gov/cef/role/N2", "longName": "995470 - Disclosure - N-2", "shortName": "N-2", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "2", "firstAnchor": { "contextRef": "Duration_12_26_2023_To_12_26_2023_pAL5-vpnDUaJhHAxg2HQTg", "name": "dei:EntityFileNumber", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "plx-20231226x8k.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "cef_EffectsOfLeverageTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "EffectsOfLeverageTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effects of Leverage [Text Block]" } } }, "auth_ref": [] }, "cef_AllRisksMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AllRisksMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "All Risks:" } } }, "auth_ref": [] }, "cef_PrimaryShelfFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PrimaryShelfFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Primary Shelf [Flag]" } } }, "auth_ref": [] }, "cef_RegisteredClosedEndFundFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RegisteredClosedEndFundFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Registered Closed-End Fund [Flag]" } } }, "auth_ref": [] }, "cef_PrimaryShelfQualifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PrimaryShelfQualifiedFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Primary Shelf Qualified [Flag]" } } }, "auth_ref": [] }, "cef_BusinessDevelopmentCompanyFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "BusinessDevelopmentCompanyFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Business Development Company [Flag]" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "cef_DividendReinvestmentAndCashPurchaseFees": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DividendReinvestmentAndCashPurchaseFees", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Dividend Reinvestment and Cash Purchase Fees" } } }, "auth_ref": [] }, "cef_IntervalFundFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IntervalFundFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Interval Fund [Flag]" } } }, "auth_ref": [] }, "cef_AnnualDividendPayment": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualDividendPayment", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment" } } }, "auth_ref": [] }, "cef_NewCefOrBdcRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "NewCefOrBdcRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "New CEF or BDC Registrant [Flag]" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "auth_ref": [] }, "cef_FeeTableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "FeeTableAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Fee Table [Abstract]" } } }, "auth_ref": [] }, "cef_ShareholderTransactionExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ShareholderTransactionExpensesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Shareholder Transaction Expenses [Table Text Block]" } } }, "auth_ref": [] }, "cef_SalesLoadPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SalesLoadPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Sales Load [Percent]" } } }, "auth_ref": [] }, "cef_UnderwritersCompensationPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "UnderwritersCompensationPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Underwriters Compensation [Percent]" } } }, "auth_ref": [] }, "cef_SecurityTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Title [Text Block]" } } }, "auth_ref": [] }, "cef_ExpenseExampleYears1to3": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleYears1to3", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 3" } } }, "auth_ref": [] }, "cef_OtherAnnualExpense3Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherAnnualExpense3Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expense 3 [Percent]" } } }, "auth_ref": [] }, "cef_OtherSecurityDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherSecurityDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Security, Description [Text Block]" } } }, "auth_ref": [] }, "cef_OtherAnnualExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherAnnualExpensesPercent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expenses [Percent]" } } }, "auth_ref": [] }, "cef_SecurityDividendsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityDividendsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Dividends [Text Block]" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "cef_EffectsOfLeverageTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "EffectsOfLeverageTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effects of Leverage [Table Text Block]" } } }, "auth_ref": [] }, "cef_NetExpenseOverAssetsPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "NetExpenseOverAssetsPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Net Expense over Assets [Percent]" } } }, "auth_ref": [] }, "cef_SecurityVotingRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityVotingRightsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Voting Rights [Text Block]" } } }, "auth_ref": [] }, "cef_WaiversAndReimbursementsOfFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WaiversAndReimbursementsOfFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Waivers and Reimbursements of Fees [Percent]" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "cef_LongTermDebtTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Title [Text Block]" } } }, "auth_ref": [] }, "cef_ExpenseExampleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example [Table Text Block]" } } }, "auth_ref": [] }, "cef_SecurityLiquidationRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityLiquidationRightsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Liquidation Rights [Text Block]" } } }, "auth_ref": [] }, "cef_AnnualCoverageReturnRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualCoverageReturnRatePercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Coverage Return Rate [Percent]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "cef_TotalAnnualExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "TotalAnnualExpensesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Total Annual Expenses [Percent]" } } }, "auth_ref": [] }, "cef_LongTermDebtPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtPrincipal", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Principal" } } }, "auth_ref": [] }, "cef_AcquiredFundFeesAndExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundFeesAndExpensesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees and Expenses [Percent]" } } }, "auth_ref": [] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelName", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ManagementFeeNotBasedOnNetAssetsNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Management Fee not based on Net Assets, Note [Text Block]" } } }, "auth_ref": [] }, "cef_SecurityLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityLiabilitiesTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Liabilities [Text Block]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "plx_DocumentAndEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://protalix.com/20231226", "localname": "DocumentAndEntityInformationAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]" } } }, "auth_ref": [] }, "cef_SecurityPreemptiveAndOtherRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityPreemptiveAndOtherRightsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Preemptive and Other Rights [Text Block]" } } }, "auth_ref": [] }, "cef_ExpenseExampleYear01": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleYear01", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example, Year 01" } } }, "auth_ref": [] }, "cef_DistributionsMayReducePrincipalTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DistributionsMayReducePrincipalTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Distributions May Reduce Principal [Text Block]" } } }, "auth_ref": [] }, "dei_PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreEffectiveAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } }, "auth_ref": [ "r0" ] }, "cef_SecurityObligationsOfOwnershipTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityObligationsOfOwnershipTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Obligations of Ownership [Text Block]" } } }, "auth_ref": [] }, "dei_PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreEffectiveAmendment", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "auth_ref": [ "r0" ] }, "cef_ReturnAtMinusTenPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtMinusTenPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Minus Ten [Percent]" } } }, "auth_ref": [] }, "cef_PreferredStockRestrictionsArrearageTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PreferredStockRestrictionsArrearageTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Restrictions, Arrearage [Text Block]" } } }, "auth_ref": [] }, "cef_PreferredStockRestrictionsOtherTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PreferredStockRestrictionsOtherTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Restrictions, Other [Text Block]" } } }, "auth_ref": [] }, "cef_ExpenseExampleYears1to5": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleYears1to5", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 5" } } }, "auth_ref": [] }, "cef_RightsSubjectToOtherThanMajorityVoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RightsSubjectToOtherThanMajorityVoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Rights Subject to Other than Majority Vote [Text Block]" } } }, "auth_ref": [] }, "cef_RightsLimitedByOtherSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RightsLimitedByOtherSecuritiesTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Rights Limited by Other Securities [Text Block]" } } }, "auth_ref": [] }, "cef_LongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt [Table Text Block]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PostEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PostEffectiveAmendment", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "auth_ref": [ "r0" ] }, "cef_ExpenseExampleYears1to10": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleYears1to10", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 10" } } }, "auth_ref": [] }, "dei_InvestmentCompanyRegistrationAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyRegistrationAmendment", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "auth_ref": [ "r15" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "us-gaap_InterestRateRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Interest Rate Risk [Member]" } } }, "auth_ref": [] }, "dei_PostEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PostEffectiveAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }, "auth_ref": [ "r0" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_InvestmentCompanyActRegistration": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyActRegistration", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "auth_ref": [ "r15" ] }, "cef_LongTermDebtStructuringTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtStructuringTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Structuring [Text Block]" } } }, "auth_ref": [] }, "cef_PurposeOfFeeTableNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PurposeOfFeeTableNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Purpose of Fee Table , Note [Text Block]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DelayedOrContinuousOffering": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DelayedOrContinuousOffering", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "auth_ref": [ "r9", "r10", "r14" ] }, "dei_InvestmentCompanyRegistrationAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "auth_ref": [ "r15" ] }, "cef_WarrantsOrRightsCalledTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WarrantsOrRightsCalledTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Title" } } }, "auth_ref": [] }, "us-gaap_NetAssetValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetAssetValuePerShare", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "NAV Per Share" } } }, "auth_ref": [] }, "cef_OtherSecurityTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherSecurityTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Security, Title [Text Block]" } } }, "auth_ref": [] }, "cef_BasisOfTransactionFeesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "BasisOfTransactionFeesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Basis of Transaction Fees, Note [Text Block]" } } }, "auth_ref": [] }, "dei_DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth_ref": [ "r9", "r10", "r14" ] }, "cef_LongTermDebtIssuanceAndSubstitutionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtIssuanceAndSubstitutionTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Issuance and Substitution [Text Block]" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "cef_LongTermDebtDividendsAndCovenantsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtDividendsAndCovenantsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Dividends and Covenants [Text Block]" } } }, "auth_ref": [] }, "cef_OtherTransactionFeesBasisNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionFeesBasisNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Note [Text Block]" } } }, "auth_ref": [] }, "cef_LongTermDebtRightsLimitedByOtherSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtRightsLimitedByOtherSecuritiesTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Rights Limited by Other Securities [Text Block]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "cef_OtherSecuritiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherSecuritiesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Securities [Table Text Block]" } } }, "auth_ref": [] }, "cef_OtherTransactionFeesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionFeesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Fees, Note [Text Block]" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r3" ] }, "cef_OtherTransactionFeesBasisMaximum": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionFeesBasisMaximum", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Maximum" } } }, "auth_ref": [] }, "cef_OtherTransactionFeesBasisMaximumPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionFeesBasisMaximumPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Maximum [Percent]" } } }, "auth_ref": [] }, "cef_OtherExpensesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherExpensesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Expenses, Note [Text Block]" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EffectiveUponFiling462e": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveUponFiling462e", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)" } } }, "auth_ref": [ "r23" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r26" ] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockLiquidationPreference", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Liquidating Preference" } } }, "auth_ref": [] }, "dei_AdditionalSecuritiesEffective413b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AdditionalSecuritiesEffective413b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "auth_ref": [ "r18" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]" } } }, "auth_ref": [] }, "dei_EffectiveWhenDeclaredSection8c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveWhenDeclaredSection8c", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)" } } }, "auth_ref": [ "r27" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Share Price" } } }, "auth_ref": [] }, "dei_EffectiveUponFiling486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveUponFiling486b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)" } } }, "auth_ref": [ "r25" ] }, "dei_EntityInvCompanyType": { "xbrltype": "invCompanyType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInvCompanyType", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)." } } }, "auth_ref": [ "r16" ] }, "dei_EffectiveOnSetDate486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnSetDate486b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)" } } }, "auth_ref": [ "r25" ] }, "dei_EffectiveOnDate486b": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnDate486b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)" } } }, "auth_ref": [ "r25" ] }, "dei_EffectiveAfter60Days486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveAfter60Days486a", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)" } } }, "auth_ref": [ "r24" ] }, "dei_EffectiveOnSetDate486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnSetDate486a", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)" } } }, "auth_ref": [ "r24" ] }, "dei_EffectiveOnDate486a": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnDate486a", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)" } } }, "auth_ref": [ "r24" ] }, "dei_NewEffectiveDateForPreviousFiling": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NewEffectiveDateForPreviousFiling", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "auth_ref": [ "r10", "r11", "r12", "r13" ] }, "dei_AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AdditionalSecurities462bFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } }, "auth_ref": [ "r20" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AdditionalSecurities462b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "auth_ref": [ "r20" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "dei_NoSubstantiveChanges462cFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "auth_ref": [ "r21" ] }, "cef_BdcFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "BdcFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "BDC File Number" } } }, "auth_ref": [] }, "dei_NoSubstantiveChanges462c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoSubstantiveChanges462c", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "auth_ref": [ "r21" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "BusinessContactMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r7", "r8" ] }, "cef_ReturnAtMinusFivePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtMinusFivePercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Minus Five [Percent]" } } }, "auth_ref": [] }, "dei_ExhibitsOnly462d": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ExhibitsOnly462d", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "auth_ref": [ "r22" ] }, "cef_OtherTransactionExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpensesAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expenses [Abstract]" } } }, "auth_ref": [] }, "cef_LowestPriceOrBid": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LowestPriceOrBid", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid" } } }, "auth_ref": [] }, "cef_IncentiveAllocationMinimumPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IncentiveAllocationMinimumPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Incentive Allocation Minimum [Percent]" } } }, "auth_ref": [] }, "cef_WarrantsOrRightsCalledAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WarrantsOrRightsCalledAmount", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Amount" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities [Table Text Block]" } } }, "auth_ref": [] }, "cef_ReturnAtPlusFivePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtPlusFivePercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Plus Five [Percent]" } } }, "auth_ref": [] }, "cef_OtherMasterFundExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherMasterFundExpensesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Master Fund Expenses [Percent]" } } }, "auth_ref": [] }, "cef_InterestExpensesOnBorrowingsPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "InterestExpensesOnBorrowingsPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Interest Expenses on Borrowings [Percent]" } } }, "auth_ref": [] }, "cef_OtherTransactionExpense3Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpense3Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expense 3 [Percent]" } } }, "auth_ref": [] }, "cef_WarrantsOrRightsCalledPeriodDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WarrantsOrRightsCalledPeriodDate", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Period [Date]" } } }, "auth_ref": [] }, "cef_AcquiredFundFeesEstimatedNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundFeesEstimatedNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees Estimated, Note [Text Block]" } } }, "auth_ref": [] }, "cef_ProspectusTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ProspectusTable", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Prospectus:" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "cef_ReturnAtPlusTenPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtPlusTenPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Plus Ten [Percent]" } } }, "auth_ref": [] }, "cef_AcquiredFundFeesAndExpensesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundFeesAndExpensesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees and Expenses, Note [Text Block]" } } }, "auth_ref": [] }, "cef_OtherTransactionExpense1Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpense1Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expense 1 [Percent]" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesAmount", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Amount (Deprecated 2023-01-31)" } } }, "auth_ref": [] }, "cef_OtherTransactionExpense2Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpense2Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expense 2 [Percent]" } } }, "auth_ref": [] }, "cef_AcquiredFundIncentiveAllocationNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundIncentiveAllocationNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Incentive Allocation, Note [Text Block]" } } }, "auth_ref": [] }, "cef_IncentiveAllocationPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IncentiveAllocationPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Incentive Allocation [Percent]" } } }, "auth_ref": [] }, "cef_EffectsOfLeveragePurposeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "EffectsOfLeveragePurposeTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effects of Leverage, Purpose [Text Block]" } } }, "auth_ref": [] }, "cef_WarrantsOrRightsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WarrantsOrRightsExercisePrice", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Exercise Price" } } }, "auth_ref": [] }, "cef_OutstandingSecuritiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecuritiesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Securities [Table Text Block]" } } }, "auth_ref": [] }, "cef_AnnualInterestRateCurrentPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualInterestRateCurrentPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Interest Rate, Current [Percent]" } } }, "auth_ref": [] }, "cef_OtherTransactionExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpensesPercent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expenses [Percent]" } } }, "auth_ref": [] }, "cef_RiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RiskAxis", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risk [Axis]" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "cef_OutstandingSecurityAuthorizedShares": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecurityAuthorizedShares", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Security, Authorized [Shares]" } } }, "auth_ref": [] }, "cef_AcquiredFundTotalAnnualExpensesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundTotalAnnualExpensesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Total Annual Expenses, Note [Text Block]" } } }, "auth_ref": [] }, "cef_OutstandingSecurityTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecurityTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Security, Title [Text Block]" } } }, "auth_ref": [] }, "cef_IncentiveAllocationMaximumPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IncentiveAllocationMaximumPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Incentive Allocation Maximum [Percent]" } } }, "auth_ref": [] }, "cef_LatestSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LatestSharePrice", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Latest Share Price (Deprecated 2023-01-31)" } } }, "auth_ref": [] }, "cef_AnnualExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualExpensesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Expenses [Table Text Block]" } } }, "auth_ref": [] }, "cef_HighestPriceOrBid": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "HighestPriceOrBid", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Highest Price or Bid" } } }, "auth_ref": [] }, "cef_OutstandingSecurityNotHeldShares": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecurityNotHeldShares", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Security, Not Held [Shares]" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "cef_FinancialHighlightsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "FinancialHighlightsAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Financial Highlights [Abstract]" } } }, "auth_ref": [] }, "cef_OutstandingSecurityHeldShares": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecurityHeldShares", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Security, Held [Shares]" } } }, "auth_ref": [] }, "cef_SharePriceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SharePriceTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Share Price [Table Text Block]" } } }, "auth_ref": [] }, "cef_ManagementFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ManagementFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Management Fees [Percent]" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Amount" } } }, "auth_ref": [] }, "cef_ProspectusLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ProspectusLineItems", "lang": { "en-us": { "role": { "label": "Prospectus [Line Items]" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "cef_LowestPriceOrBidNav": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LowestPriceOrBidNav", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid, NAV" } } }, "auth_ref": [] }, "cef_ReturnAtZeroPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtZeroPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Zero [Percent]" } } }, "auth_ref": [] }, "cef_DividendAndInterestExpensesOnShortSalesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DividendAndInterestExpensesOnShortSalesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Dividend and Interest Expenses on Short Sales [Percent]" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesCvgPerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesCvgPerUnit", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Coverage per Unit" } } }, "auth_ref": [] }, "cef_IncentiveFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IncentiveFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Incentive Fees [Percent]" } } }, "auth_ref": [] }, "cef_HighestPriceOrBidNav": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "HighestPriceOrBidNav", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Highest Price or Bid, NAV" } } }, "auth_ref": [] }, "cef_DistributionServicingFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DistributionServicingFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Distribution/Servicing Fees [Percent]" } } }, "auth_ref": [] }, "cef_OtherAnnualExpense1Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherAnnualExpense1Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expense 1 [Percent]" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "cef_SeniorSecuritiesCoveragePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesCoveragePerUnit", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Coverage per Unit (Deprecated 2023-01-31)" } } }, "auth_ref": [] }, "cef_HighestPriceOrBidPremiumDiscountToNavPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "HighestPriceOrBidPremiumDiscountToNavPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Highest Price or Bid, Premium (Discount) to NAV [Percent]" } } }, "auth_ref": [] }, "cef_RiskTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RiskTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risk [Text Block]" } } }, "auth_ref": [] }, "cef_LoanServicingFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LoanServicingFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Loan Servicing Fees [Percent]" } } }, "auth_ref": [] }, "cef_AnnualInterestRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualInterestRatePercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Interest Rate [Percent]" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Involuntary Liquidating Preference per Unit (Deprecated 2023-01-31)" } } }, "auth_ref": [] }, "cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "CapitalStockLongTermDebtAndOtherSecuritiesAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Capital Stock, Long-Term Debt, and Other Securities [Abstract]" } } }, "auth_ref": [] }, "dei_InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyActFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "auth_ref": [ "r10", "r11", "r12", "r13" ] }, "cef_LatestNav": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LatestNav", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Latest NAV (Deprecated 2023-01-31)" } } }, "auth_ref": [] }, "cef_AnnualDividendPaymentInitial": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualDividendPaymentInitial", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment, Initial" } } }, "auth_ref": [] }, "cef_OtherFeederFundExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherFeederFundExpensesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Feeder Fund Expenses [Percent]" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesHighlightsAnnualizedNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesHighlightsAnnualizedNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Highlights Annualized, Note [Text Block]" } } }, "auth_ref": [] }, "cef_SharePricesNotActualTransactionsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SharePricesNotActualTransactionsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Share Prices Not Actual Transactions [Text Block]" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities, Note [Text Block]" } } }, "auth_ref": [] }, "cef_LowestPriceOrBidPremiumDiscountToNavPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LowestPriceOrBidPremiumDiscountToNavPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid, Premium (Discount) to NAV [Percent]" } } }, "auth_ref": [] }, "cef_DividendExpenseOnPreferredSharesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DividendExpenseOnPreferredSharesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Dividend Expenses on Preferred Shares [Percent]" } } }, "auth_ref": [] }, "cef_AnnualInterestRateInitialPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualInterestRateInitialPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Interest Rate, Initial [Percent]" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesAverageMarketValuePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesAverageMarketValuePerUnit", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Average Market Value per Unit" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r6" ] }, "cef_NoPublicTradingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "NoPublicTradingTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "No Public Trading [Text Block]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "cef_OtherAnnualExpense2Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherAnnualExpense2Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expense 2 [Percent]" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesHeadingsNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesHeadingsNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Headings, Note [Text Block]" } } }, "auth_ref": [] }, "cef_OtherAnnualExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherAnnualExpensesAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expenses [Abstract]" } } }, "auth_ref": [] }, "cef_AnnualDividendPaymentCurrent": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualDividendPaymentCurrent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment, Current" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesAveragingMethodNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesAveragingMethodNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Averaging Method, Note [Text Block]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r19" ] }, "cef_SeniorSecuritiesHighlightsAuditedNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesHighlightsAuditedNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Highlights Audited, Note [Text Block]" } } }, "auth_ref": [] }, "cef_GeneralDescriptionOfRegistrantAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "GeneralDescriptionOfRegistrantAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "General Description of Registrant [Abstract]" } } }, "auth_ref": [] }, "cef_InvestmentObjectivesAndPracticesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "InvestmentObjectivesAndPracticesTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Objectives and Practices [Text Block]" } } }, "auth_ref": [] }, "cef_NoTradingHistoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "NoTradingHistoryTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "No Trading History [Text Block]" } } }, "auth_ref": [] }, "cef_RiskFactorsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RiskFactorsTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risk Factors [Table Text Block]" } } }, "auth_ref": [] }, "cef_LatestPremiumDiscountToNavPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LatestPremiumDiscountToNavPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Latest Premium (Discount) to NAV [Percent]" } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "cef_CapitalStockTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "CapitalStockTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Capital Stock [Table Text Block]" } } }, "auth_ref": [] }, "dei_ExhibitsOnly462dFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ExhibitsOnly462dFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "auth_ref": [ "r22" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form F-3" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-3" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-4" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-6" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form S-3" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Investment Company Act", "Number": "270" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "313" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "413", "Subsection": "b" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r20": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "b" }, "r21": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "c" }, "r22": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "d" }, "r23": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "e" }, "r24": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "a" }, "r25": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "b" }, "r26": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r27": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Section": "8", "Subsection": "c" } } } ZIP 16 0001558370-23-020006-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-020006-xbrl.zip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end